Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -575,000 | -569,000 | -607,000 | -707,421 | -454,025 |
| Depreciation Amortization | 31,000 | 23,000 | 13,000 | 20,919 | 19,845 |
| Income taxes - deferred | N/A | N/A | N/A | -1,639 | N/A |
| Accounts receivable | -31,000 | -34,000 | -23,000 | -12,068 | -5,432 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | N/A | 32,313 |
| Other Working Capital | -23,000 | 14,000 | -16,000 | 61,874 | -63,236 |
| Other Operating Activity | 132,000 | 152,000 | 158,000 | 257,870 | 131,840 |
| Operating Cash Flow | $-466,000 | $-414,000 | $-475,000 | $-380,465 | $-338,695 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 258,000 | 4,000 | 221,000 | -79,754 | -201,180 |
| PPE Investments | -6,000 | -7,000 | -44,000 | -116,123 | -73,093 |
| Net Acquisitions | N/A | N/A | N/A | -75,025 | N/A |
| Sale Of Investment | N/A | N/A | N/A | 10,094 | 79,843 |
| Purchase Sale Intangibles | -15,000 | -13,000 | -3,000 | -30,000 | N/A |
| Other Investing Activity | -16,000 | -15,000 | -9,000 | -30,844 | -942 |
| Investing Cash Flow | $236,000 | $-18,000 | $168,000 | $-291,652 | $-195,372 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 86,000 | 399,000 | 387,000 | 10,813 | 119,044 |
| Other Financing Activity | 392,000 | 0 | 1,000 | 490,395 | -492 |
| Financing Cash Flow | $478,000 | $399,000 | $388,000 | $501,208 | $118,552 |
| Exchange Rate Effect | 4,000 | -2,000 | N/A | -1,075 | -1,194 |
| Beginning Cash Position | 184,000 | 219,000 | 138,000 | 309,585 | 726,294 |
| End Cash Position | 436,000 | 184,000 | 219,000 | 137,601 | 309,585 |
| Net Cash Flow | $252,000 | $-35,000 | $81,000 | $-171,984 | $-416,709 |
| Free Cash Flow | |||||
| Operating Cash Flow | -466,000 | -414,000 | -475,000 | -380,465 | -338,695 |
| Capital Expenditure | -6,000 | -7,000 | -44,000 | -116,123 | -73,093 |
| Free Cash Flow | -472,000 | -421,000 | -519,000 | -496,588 | -411,788 |